Vaccination strategy against pneumococcal infections - Place of the VAXNEUVANCE vaccine in children aged 6 weeks to 18 years

The Vaxneuvance vaccine is a pneumococcal conjugate vaccine directed against 15 pneumococcal serotypes. It received European Marketing Authorization on December 13 for people aged 18 and over and an extension of Marketing Authorization was obtained on October 21, 2022 for infants, children and adolescents aged 6 weeks to less than 18 years. The MSD laboratory contacted the HAS for a request to integrate the Vaxneuvance vaccine into the current vaccination strategy for the prevention of pneumococcal infections in infants, children and adolescents under 18 years of age.